StockTipsArenaBeta

BUY Paras Healthcare Limited — Choice Broking

BUYParas Healthcare Limited
Paras Healthcare share price target & all analyst calls

byChoice BrokingHorizon: NA (inferred 1 year)7 Nov 2026via Moneycontrol Broker Research

Entry₹753.55Inferred
Target₹900
Total upside +19.43% (call closed)
Stop lossNot given
Exit₹90012 Nov 2026, 10:50 am
Target hit+19.43%0.00%upside left
Follow Choice Broking for new calls(100% target hit, 27 closed calls)Get alertsWatch PARASHLTH for new buy/sell callsGet alertsSee 273 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 12 Nov 2026
4 supporting2 neutral0 opposing
Supports the BUY call (4)

Paras Healthcare posts Rs 40 crore Q2 net profit in first results after listing

NewsEt-Markets·5 Nov · 6d ago

(opens in new tab)

Paras Healthcare reported standalone and consolidated financial results for the quarter and half year ended September 30, 2026, showing growth in revenue and profit compared to the previous year.

BSE · Board Meeting·5 Nov · 6d ago

(opens in new tab)

Paras Healthcare shares: After IPO listing gains, check what's happening with stock - Buy, sell or hold?Experts weigh in

NewsLivemint·29 Oct · 2w ago

(opens in new tab)

Paras Healthcare Listing Today: IPO subscribed 2.23 times; grey market premium at ₹13

NewsCnbc-Tv18·28 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Paras Healthcare shares to list today: Check GMP ahead of debut

NewsEt-Markets·28 Oct · 2w ago

(opens in new tab)

Jio Platforms Vs Paras Healthcare: What Does GMP Indicate Ahead Of Listing?

NewsNdtv-Profit·28 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

More from Choice Broking

Every call and its outcome